Galderma
Galderma, the pure-play dermatology category leader, delivered record 2025 net sales of $5.21 billion (up 17.7% constant currency) with core EBITDA of $1.21 billion, anchored by the Restylane cross-linked HA filler line.
- Country
- Switzerland
- Ticker
- SIX:GALD
Cross-linked HA filler
CE Marked
FDA approved
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| specialty-fine-chem | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biosynthetic hyaluronic acid | specialty-fine-chem | Low | → |
| Recombinant botulinum toxin (biosynthetic Botox) | specialty-fine-chem | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.